This is a working overview of freeze–thaw cycle, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-21. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Oxyntomodulin (often abbreviated OXM) is a naturally occurring 37-amino acid peptide hormone found in the colon, produced by the oxyntic (fundic) cells of the oxyntic (fundic) mucosa. It has been found to suppress appetite. The mechanism of action of oxyntomodulin is not well understood. It is known to bind both the GLP-1 receptor and the glucagon receptor, but it is not known whether the effects of the hormone are mediated through these receptors or through an unidentified receptor. Oxyntomodulin has been linked to entrainment of the liver's circadian clock. Oxyntomodulin has been investigated as a blood-glucose regulation agent in connection with diabetes.
This is a list of Trotskyist internationals. It includes all of the many political internationals which self-identify as Trotskyist. Of the organizations listed, two claim to be the original Fourth International founded in 1938: the reunified Fourth International (USFI) and the International Committee of the Fourth International (ICFI). The Fourth International split into two factions 1953 over the question of historic perspective, with the International Secretariat (ISFI) turning in favour of deep entryism and supporting petty-bourgeois nationalist movements in less developed countries, and the International Committee (ICFI) upholding the need to form revolutionary parties. The factions reunited in 1963 resulting in the formation of reunified Fourth International (USFI), while parts of the ICFI did not. Both the USFI and ICFI went on to fragment further, giving rise to several new internationals. Certain organizations which claim to be Trotskyist make no attempt to claim any relationship to the Fourth International in an organizational sense and argue that it no longer exists. Some claim to represent a continuity from the Fourth International or to have re-established it: for example the Fourth International (ICR) International Centre/Center of Reconstruction, also known as the FI (La Verité), also calls itself the "Fourth International". The various organizations listed here range in size from those having thousands of adherents in dozens of countries to tendencies which can barely claim a dozen members in three or four countries.
== Research == Ala-Kokko's research focuses on collagen in cartilage, and connective tissue disorders. She has, with her research group, succeeded in identifying the errors in cartilage collagen that lead to the development of osteoarthritis and diseases of the vertebrae, amongst others. Her results have assisted in the diagnosis and care of patients, as well as improvements to the way in which these diseases are treated. She has published about 160 articles based on her research, and she has been awarded five patents.
Sources: en.wikipedia.org
== Possible Complications == As described above, when a fistulectomy is performed to remove an anorectal fistula tract that involves the anal sphincters, a common complication that may occur is fecal incontinence. The degree of incontinence can be measured using the Wexner score, which can allow surgeons to monitor the progression of incontinence post-operatively. As with other surgeries, fistulectomies may also pose other complications such as delayed wound healing and infection.
12 June – The Green Party launches its manifesto, with key points including increasing taxes for the better off, and higher spending on healthcare, housing and climate change. Sky News presenter Beth Rigby presents an election debate from Grimsby Town Hall, where Sunak and Starmer face questions from an audience. Craig Williams, who served as Sunak's Parliamentary Private Secretary, is being investigated by the Gambling Commission after placing a bet on the date of the general election. Williams subsequently describes the bet as a "huge error of judgement". Dr Anne McCloskey, an independent general election candidate for Foyle, is sentenced to 14 days in prison for non-payment of a COVID-19 related fine by Derry Magistrates. Police say they are aware of YouTuber and internet prankster Niko Omilana, who has registered himself as a general election candidate in 11 different constituencies. 13 June – Keir Starmer unveils the Labour Party's general election manifesto. He says that wealth creation is the "number one priority" and that Labour will focus on economic growth. The Green Party is forced to temporarily remove its manifesto from its website after facing criticism for using an image of an ill man to illustrate its policy on HIV. Plaid Cymru launches its 2024 election manifesto, which includes plans for Welsh independence, 500 extra GPs and funding from rail improvements.
Acetylcysteine or N-acetylcysteine (NAC) is a mucolytic that is used to treat paracetamol (acetaminophen) overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders, such as pneumonia and bronchitis. It has been used to treat lactobezoar in infants. It can be taken intravenously, orally (swallowed by mouth), or by inhalation by use of a nebulizer. It is also sometimes used as a dietary supplement. Common side effects include nausea and vomiting when taken orally. The skin may occasionally become red and itchy with any route of administration. A non-immune type of anaphylaxis may also occur. It appears to be safe in pregnancy. For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralize the toxic breakdown products of paracetamol. When inhaled, it acts as a mucolytic by decreasing the thickness of mucus. Acetylcysteine was initially patented in 1960 and came into medical use in 1968. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
Sources: en.wikipedia.org
While arsenic presents no radiological hazard, it is extremely chemically toxic. If it is desired to get rid of arsenic (no matter its origin), thermal neutron irradiation of the only stable isotope 75As will yield short lived 76As which quickly decays to stable 76Se. If arsenic is irradiated with sufficient fast neutrons to cause notable "knockout" (n,2n) or even (n,3n) reactions, Isotopes of germanium will be produced instead.
Ana María Muñoz Jauregui (born 1969, Lima) is a Peruvian pharmacist, biochemist and nutritionist. She has served as Rector and, since 2023, as the Vice Rector of research at San Ignacio de Loyola University (USIL). Muñoz has authored numerous publications and received national and international awards, such as silver, gold medals and semi-grand prize wins at the International KIWIE Award.
== Biological significance and potential pharmacological utility == As a natural product, coicenals have been tested for their pharmacological utility. One study showed that coicenals exhibit moderate inhibitory activity against nitric oxide released from macrophages. Since nitric oxide is crucial to inflammatory processes, this biological ability could translate to medicinal use for treating inflammatory diseases. Coicenal C has also demonstrated its ability to inhibit the growth of Bacillus subtilis and Staphylococcus aureus. Coicenals A, B, and D do not bear this ability, however.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.